Observational studyFuture oncology (London, England)2026
Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia.
Observational study in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSecond-generation covalent Bruton tyrosine kinase inhibitors (cBTKi), acalabrutinib and zanubrutinib, are standard-of-care for treatment-naïve adults with chronic lymphocytic leukemia (CLL). However, real-world evidence remains limited.
methodsThis real-world analysis compared acalabrutinib and zanubrutinib using the IntegraConnect PrecisionQ de-identified electronic health record database, representing >3 million cancer patients across 500+ US sites. Patients initiated cBTKi between January 2020 and November 2023, with follow-up through 3 July 2024.
resultsThis study included 473 patients; 184 zanubrutinib-treated patients matched to 289 acalabrutinib-treated patients by age and sex. Baseline characteristics were similar. Median time to discontinuation (TTD) for acalabrutinib was 29.5 months (95% confidence interval [CI] 21.2, not reached [NR]). Median TTD for zanubrutinib was NR, with significantly longer duration of treatment than acalabrutinib (adjusted hazard ratio [aHR]: 0.50, 95% CI 0.3-0.7;
conclusionZanubrutinib demonstrated longer treatment persistence and fewer discontinuations attributed to toxicity during chart abstraction than acalabrutinib in treatment-naïve CLL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.